RxDoctor Payments Data

Ayodele Osowo, MD

Gastroenterology · Orland Park, ILNPI 1063552479

Payments from drug & device makers

$6,786in general payments, 2019–2025

Across 388 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$631
  • Johnson & Johnson$562
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$412
  • Gilead$251
  • QOL Medical, LLC$250
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$6,52696%
  • Education$2604%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,786 in reported general payments places this provider in the 70th percentile of 787 gastroenterology providers in Illinois.

See all gastroenterology providers in Illinois

Medicare billing

Part B allowed, 2024
$98,692
Medicare patients
312
Services billed
907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab26$385,283
RinvoqUpadacitinib16$116,661
LinzessLinaclotide46$33,589
CreonLipase/Protease/Amylase11$20,411
SutabSod Sulf/Pot Chloride/Mag Sulf86$14,138
TrulancePlecanatide22$12,299
ClenpiqSod Picosulf/Mag Ox/Citric Ac39$6,792
Mesalamine13$4,649
Lubiprostone18$2,045
CholestyramineCholestyramine (With Sugar)24$1,644
Ursodiol25$1,374
Omeprazole72$816
Famotidine45$655
Azathioprine29$487
Pantoprazole Sodium72$438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Linzess, Creon$2,789$170,66173 claims
Braintree Laboratories, Inc.Sutab$80$14,13886 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$412$12,29922 claims
Ferring Pharmaceuticals Inc.Clenpiq$45$6,79239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 787 gastroenterology providers in Illinois.

Other gastroenterology in Orland Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →